Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MNKD
SELLMannKind Corporation · Healthcare · United States · $1.3B · Avg Vol: $20M/d
COMPANY DESCRIPTION
MannKind Corporation is a biopharmaceutical company developing and commercializing inhaled therapeutic products, primarily for endocrine and orphan lung diseases, including Afrezza, an inhaled insulin. It possesses a proprietary Technosphere® drug delivery platform, enabling rapid absorption of therapeutic proteins and peptides via inhalation. MannKind is a niche player leveraging unique drug delivery technology to address unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 99.8M | 199.0M | 285.5M | 349.0M | 51.8% | 360.8M | 462.9M | 521.6M | 22.3% |
| EPS | -0.34 | -0.04 | 0.10 | 0.02 | -80.0% | -0.07 | — | — | — |
| Shares | 263.8M | 270.0M | 303.0M | 307.8M | +16.7% | 309.0M | — | — | — |
| Debt | 278.8M | 272.6M | 50.1M | 367.4M | 9.6% | 434.2M | — | — | — |
| Equity | -250.5M | -246.2M | -78.8M | -51.0M | — | — | — | — | — |
| Op CF | -80.7M | 34.1M | 42.5M | 18.3M | -26.8% | 19.3M | — | — | — |
| Inv CF | 4.9M | -2.0M | -96.6M | -304.8M | — | — | — | — | — |
| Fin CF | 21.4M | 136.6M | -137.3M | 315.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MNKD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MNKD | MannKind Corporation(you) | $1.3B | 23 | SELL |
| ABSI | Absci Corporation | $1.3B | 22 | SELL |
| ARDX | Ardelyx, Inc. | $1.2B | 22 | SELL |
| ORIC | ORIC Pharmaceuticals, Inc. | $1.3B | 21 | SELL |
| SVRA | Savara Inc. | $1.1B | 19 | STRONG SELL |
| JANX | Janux Therapeutics, Inc. | $935M | 24 | SELL |
| AVTX | Avalo Therapeutics, Inc. | $976M | 25 | SELL |
| TSHA | Taysha Gene Therapies, Inc. | $1.6B | 19 | STRONG SELL |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | 29 | SELL |
| PHAT | Phathom Pharmaceuticals, Inc. | $912M | 21 | SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%